Tumor necrosis factor (TNF)-induced ICAM-1 in endothelial cells (EC) promotes leukocyte adhesion. Here we report that ICAM-1 also effects EC barrier function. Control-or E-selectin-transduced human dermal microvascular EC (HDMEC) form a barrier to flux of proteins and to passage of current (measured as transendothelial electrical resistance or TEER). HDMEC transduced with ICAM-1 at levels comparable to that induced by TNF show reduced TEER, but do so without overtly changing their cell junctions, cell shape, or cytoskeleton organization. Higher levels of ICAM-1 further reduce TEER, increase F/G-actin ratios, rearrange the actin cytoskeleton to cause cell elongation, and alter junctional zona occludens 1 and vascular endothelialcadherin staining. Transducing with ICAM-1 lacking an intracellular region also reduces TEER. TNF-induced changes in TEER and shape follow a similar time course as ICAM-1 induction; however, the fall in TEER occurs at lower TNF concentrations. Inhibiting NF-kB activation blocks ICAM-1 induction; TEER reduction, and shape change. Specific small-interfering RNA knockdown of ICAM-1 partially inhibits TNF-induced shape change. We conclude that moderately elevated ICAM-1 expression reduces EC barrier function and that expressing higher levels of ICAM-1 affects cell junctions and the cytoskeleton. Induction of ICAM-1 may contribute to but does not fully account for TNF-induced vascular leak and EC shape change.
INTRODUCTION
Acute inflammation is characterized by a number of changes in local microvessels, including increased leakiness to plasma proteins and increased adhesion of circulating leukocytes to the endothelial cell (EC) lumenal surface (Pober and Cotran, 1991) . Plasma protein extravasation is responsible for the classical inflammatory sign of ''tumor'', commonly referred to in skin as edema or induration, and serves to create a provisional matrix within the tissue that can support leukocyte diapedesis. Vascular leakiness may sometimes become more widespread, involving one or more organs, for example in settings of acute respiratory distress syndrome or in systemic sepsis (Crowley, 1996; Groeneveld, 2002) . The early changes underlying vascular leakiness have been attributed to concomitant alterations in EC shape and in cell junctions, described as ''retraction'' or ''contraction'', or viewed as inter-endothelial gap formation, respectively (Majno and Palade, 1961; Majno et al., 1969; Wysolmerski and Lagunoff, 1990; McDonald et al., 1999) . These morphological changes represent a maximal cytokine response, and protein extravasation may be initiated by more subtle alterations in the endothelial lining.
Leukocyte adhesion involves the transcription and expression of new surface proteins (adhesion molecules) on EC that bind to counter-receptors on circulating leukocytes (von Andrian and Mackay, 2000; Kluger, 2004) . Many of these adhesion molecules, including ICAM-1; (CD54) and Eselectin (E-sel) (CD62E), are induced by tumor necrosis factor (TNF; Pober et al., 1986b; Detmar et al., 1990; Richard et al., 1998) . Although the regulation of expression of various adhesion molecules differ in detail, all depend upon the transcription factor NF-kB, which is activated by TNF or other proinflammatory cytokines (Collins et al., 1995) . Intradermal injection of TNF causes adhesion molecule expression and local extravasation of leukocytes (Munro et al., 1989) . TNF is also sufficient to produce vascular leak in vivo, for example during cytokine-based immunotherapy (Cotran et al., 1988; Lo et al., 1992; Dubinett et al., 1994; Thom et al., 1995) . In cell culture, TNF causes EC to undergo cytoskeletal and junctional rearrangements and shape changes (Stolpen et al., 1986; Blum et al., 1997) . In particular, actin filaments, concentrated along cell-cell junctions in resting cells, may reorganize as thickened bands or as centrally distributed stress fibers (Stolpen et al., 1986; Wojciak-Stothard et al., 1998) . These TNF-induced cytoskeletal changes have been linked to an increase in filamentous (F-) and a simultaneous decrease in globular (G-) actin content (Wojciak-Stothard et al., 1998; Nwariaku et al., 2003) . However, the mechanism of such responses to TNF is less well understood than is induction of adhesion molecules. In the present report, we explore the hypothesis that vascular leakiness is mechanistically coupled to adhesion molecule induction, especially of ICAM-1. We propose this concept based on the observations that inflammation-associated leakiness is reduced in ICAM-1 À/À mice (Sligh et al., 1993; Xu et al., 1994) and that the intracellular cytoplasmic tail of ICAM-1 interacts directly with actin-binding proteins, such as actinin, ezrin, and moesin (Carpen et al., 1992; Heiska et al., 1998; Barreiro et al., 2002) . In addition, when crosslinked by antibody or engaged by leukocytes, ICAM-1 can reorganize the actin cytoskeleton (Amos et al., 2001; Wang et al., 2002) by acting through a Rho-dependent pathway (Adamson et al., 1999) . Here we show that simple overexpression of ICAM-1 in cultured human dermal microvascular EC (HDMEC) can cause vascular leakiness as well as EC shape change, cytoskeletal reorganization, and junctional protein alterations in the absence of crosslinking or leukocyte binding. Like ICAM-1 induction, TNF-induced leakiness and shape change require NF-kB-induced protein synthesis. However, our studies using siRNA suggest that even though increased expression of ICAM-1 contributes to TNF-initiated responses, it does not wholly account for them.
RESULTS

Effects of ICAM-1 overexpression
Cultured HDMEC grown to confluence on fibronectin-coated transwell inserts form a monolayer that resists the passage of electrical current, which may be quantified as a transendothelial electrical resistance (TEER). To examine the effects of ICAM-1 expression on barrier function, we produced a series of retrovirally transduced HDMEC cell lines. These consisted of cell lines that expressed ICAM-1, E-sel, or control transductants (made with empty viral vector). By FACS analysis, control transductants expressed ICAM-1 at levels comparable to basal expression on non-transduced HDMEC, and are therefore designated as ICAM-1 basal . Cell lines that expressed ICAM-1 at levels comparable to that seen following TNF are designated as ICAM-1 med and cell lines that expressed approximately 8-fold higher levels are designated as ICAM-1 high . Neither ICAM-1 basal , ICAM-1 med , nor ICAM-1 high expressed E-sel. E-sel transductants E-sel expressed E-sel at levels comparable to that observed in TNFtreated HDMEC, but remained at basal levels for ICAM-1 (Figure 1a) . We plated E-sel, ICAM-1 basal , and ICAM-1 med on fibronectin-coated transwells and measured TEER on a daily basis as the cells reached confluence. TEER increased daily, reaching a plateau of maximal TEER 48-72 hours post-visual confluence. The level of TEER achieved by ICAM-1 med monolayers was significantly lower than that achieved by ICAM-1 basal or E-sel (shown in Figure 1b , upper panel). ICAM-1 high monolayers established very little TEER, approaching that of naked transwells (Figure 1b, lower panel) . The effects of different levels of transduced ICAM-1 expression on TEER were reproducible in three separately derived sets of transductants, analyzed in multiple independent experiments.
To determine if the fall in monolayer TEER observed with increasing ICAM-1 expression by HDMEC represents a change in macromolecular permeability, we cultured ICAM-1 basal , ICAM-1 med , and ICAM-1 high HDMEC transductants on transwells until TEER became maximal and measured the transmonolayer flux of FITC-tagged BSA. The flux of FITC-BSA across naked transwells was much greater than across transwells containing post-confluent HDMEC, indicating that HDMEC formed a monolayer with barrier function toward BSA (data not shown). The passage of FITC-BSA accelerated with increasing levels of HDMEC ICAM-1 expression (Figure 1c ), and as reported by others (Marcus and Gewertz, 1998 ) the rate of protein flux was inversely proportional to TEER. These differences in transmonolayer flux of BSA and in TEER cannot be ascribed to reduced cell density, as ICAM-1 med and ICAM high cells reached equivalent if not greater numbers at 48 hours post-confluence than did ICAM-1 basal or E-sel (data not shown). The creation of an endothelial barrier has been correlated with the organization of actin filaments into dense peripheral bands; vascular leakiness occurs at sites where actin filaments rearrange into longitudinal stress fibers (Stolpen et al., 1986; Brett et al., 1989) . This reorganization of actin filaments also results in a change in cell shape from polygonal to elongated (Wojciak-Stothard et al., 1998) . These observations have been used to infer that a reorganization of the actin cytoskeleton underlies the development of leakiness. To examine this hypothesis, we quantified cell shape in confluent monolayers of our transductants by determining ratios of the longest to the shorter perpendicular axis of HDMEC (an ''axis ratio'') from morphometrical measurements, using the staining pattern of the junctional protein vascular endothelial (VE)-cadherin as a guide. The majority of ICAM-1 high cells were elongated in cell shape relative to ICAM-1 basal controls or E-sel HDMEC (quantified morphometrically in Table 1 ). This difference in ICAM-1 high shape could also be visualized by phalloidin staining as a thickening of the actin stress fibers (Figure 2a) . Importantly, despite lower TEER relative to ICAM basal , visible elongation and reorganization of actin filaments were not observed for ICAM med . As TNF-induced leakiness has been correlated with an increase in the filamentous (F-) to monomeric (G-) actin ratio (Wojciak-Stothard et al., 1998), we examined whether this ratio may be directly affected by ICAM-1. Compared to E-sel, the F/G actin ratio is increased nearly 3-fold in ICAM high transductants by immunoblot analysis of lysates obtained by differential detergent extraction (Figure 2b ). However, no increase in the F/G actin ratio of ICAM med was observed relative to that of E-sel or ICAM basal (in two independent experiments with two different HDMEC lines; data not shown). These results suggest that re-organization of the actin cytoskeleton underlies shape changes we observed at higher levels of ICAM-1 expression. However, higher levels of ICAM-1 are required to reorganize the actin cytoskeleton than are required to reduce TEER.
Two different types of intercellular junctions composed of different molecular structures normally maintain permselectivity of EC to blood macromolecules, namely tight junctions, formed by occludin, claudins, junctional adhesion molecules and associated zona occludens 1 (ZO-1), and adherens junctions, formed by VE-cadherin and catenins (Stevens et al., 2000; Bazzoni and Dejana, 2004) . As TNF treatment disrupts the otherwise continuous staining patterns of junctional molecules like ZO-1 (at tight junctions, Blum et al., 1997) and VE-cadherin (at adherens junctions; Wojciak-Stothard et al., 1998; Corada et al., 1999) we examined whether the distribution patterns of these proteins might be affected by increased ICAM-1. The immunostaining patterns for VE-cadherin and ZO-1 were disjoined and fainter in ICAM high compared to E-sel and ICAM med transductants, which more closely resembled ICAM basal (non-transduced) control HDMEC (Figure 3 ). Compared with other HDMEC transductants, VE-cadherin, and ZO-1 immunostaining patterns of ICAM high appeared visibly fragmented and interdigitized along the paracellular boundaries. We quantified Day on transwell patterns of immunostained junctions using morphometry software (Image J) according to a method established by others (Macconi et al., 2006) . For two different lines of ICAM high , the number of tight junction-associated ZO-1 segments increased and the length per segment decreased compared to E-sel control HDMEC (Tables 2 and 3) . Again compared with E-sel, in ICAM med the number of ZO-1 segments increased and length per segment decreased, but to a lesser extent than for ICAM high (Table 2 ). However, this comparison did not reach statistical significance in the (Table 3 ). E-sel measurements were comparable to those of non-transduced HDMEC by this analysis (data not shown). Extensive redistribution of VE-cadherin surface expression away from intercellular adherens junctions was observed in paraformaldehyde-fixed ICAM high that prevented evaluation by this method (data not shown). In ethanol-and acetic acid-fixed ICAM high , however, intracellular, presumably cytoskeletonassociated VE-cadherin could be evaluated and by this approach the number of adherens junction-associated VEcadherin segments was increased and the segment length decreased compared to E-sel control HDMEC (Table 3) . For ICAM med , the number of adherens junction-associated VEcadherin segments increased in one of the two lines examined, but there were no differences measured in segment length (Tables 2 and 3 ). These measurements support visually apparent differences in ICAM high ZO-1 and VE-cadherin immunostaining and suggest that more subtle junctional differences among ICAM med and E-sel control are detectable, but vary among the two lines of transductants examined.
Our initial hypothesis was that because ICAM-1 interacts with the actin cytoskeleton through its intracellular region, increased levels of ICAM-1 expression would perturb the actin cytoskeleton, affecting cell junctions, and paracellular permeability. However, the experiments described above suggest that effects on permeability may be uncoupled from effects on the cytoskeleton requiring higher levels of ICAM-1 expression. To explore this idea further we generated a truncated form of ICAM-1 that lacked all but one residue of the ICAM-1 cytoplasmic domain (ICAM DCyto ) and should thus be incapable of directly interacting with the actin cytoskeleton. As only a portion of HDMEC expressed ICAM DCyto above basal levels following our standard transduction procedure, we isolated this population by FACSort ( Figure  S1 ). In two different lines of transduced HDMEC, TEER was lower in FACSorted ICAM DCyto than in ICAM basal and E-sel, but in each case not as low as in ICAM high (Figure 4 ). These results suggest that regions outside of the ICAM-1 cytoplasmic domain can contribute to vascular leakiness.
Effects of TNF-treatment on ICAM-1 expression, leakiness, and shape change
As overexpressing ICAM-1 in HDMEC was observed to cause changes in TEER and cytoskeletal organization resembling those caused by TNF, we assessed the potential contributions of ICAM-1 to TNF-induced leakiness by comparing the quantitative and kinetic relationships of TNF-induced ICAM-1 expression to TNF-induced changes in TEER and shape. We first added 10 ng/ml TNF to a confluent HDMEC monolayer and followed the effect on ICAM-1 expression over time. TNF-treated HDMEC showed no change in their basal expression level of ICAM-1 for at least 1 hour, markedly increased their expression level at 4 hours and even further increased their expression level at 24 hours (Figure 5a ). In replicate TNF-treated HDMEC cultures we observed that the time dependence of the TEER response was similar to that observed for induction of ICAM-1 expression; TEER was sustained for at least 1 hour before decreasing at 4 hours, and falling even further by 24 hours, compared to a vehicletreated monolayer (Figure 5b ). The time dependence of the TNF-induced HDMEC elongation response was somewhat slower than those of ICAM-1 expression or TEER, not changing during the first 4 hours but visually apparent at 24 hours ( Figure 5c ). TNF-treated HDMEC that had undergone shape change also showed a 6-fold increase in actin polymerization ( Figure 2b ). We then compared the HDMEC response of TNF to that of thrombin, an agent known to cause rapid increases in vascular permeability. In contrast to the TNF response, thrombin caused a fall of TEER within 10 minutes that returned to baseline by 24 hours (Figure 5b ).
Moreover, unlike TNF, thrombin did not increase expression of ICAM-1 or change HDMEC shape, further emphasizing that differing mechanisms underlie the actions of these two inflammatory mediators (data not shown).
We next examined the concentration dependence of these three responses at 48 hours of TNF treatment. Pilot experiments established that all three TNF-induced changes were maximal at 10 ng/ml. A 50% maximal change in ICAM-1 expression and in cell elongation each occurred at 1.1 ng/ml TNF. In contrast, only 0.13 ng/ml was required to produce a 50% of maximum fall in TEER (Figure 5d-f) . Collectively, these data suggest that while increased ICAM-1 expression may contribute to TNF-induced leakiness, it does not wholly account for it.
Contributions of increased ICAM-1 expression to TNF-induced leakiness and shape change To more directly assess the contributions of ICAM-1 to TNFinduced leakiness and EC shape change, we pursued two parallel strategies. First, we blocked ICAM-1 induction by interference with TNF-induced gene transcription. Many TNF-induced transcriptional events in EC, including that of ICAM-1, are controlled by NF-kB activation, which is repressed by IkBa in the absence of TNF (Collins et al., 1995) . TNF-mediated NF-kB activation can be blocked by www.jidonline.org 767 overexpression of a mutagenized S32/36A IkBa that acts as a ''super repressor'', designated SRIkB. Compared to enhanced green fluorescent protein transductants, SRIkB-HDMEC showed reduced nuclear translocation of Rel A (also known as the p65 subunit of NF-kB) in response to TNF (data not shown) and reduced (but did not eliminate) basal and inducible expression of ICAM-1 ( Figure S2 ). Strikingly, SRIkB-transduced HDMEC did not lose TEER in response to TNF (through 48 hours) despite retaining a rapid TEER loss in response to thrombin (Figure 6 ). TNF also failed to induce shape change in SRIkB-transduced HDMEC derived from two different skin sources (quantified in Table 4 ) an inhibition that was clearly visible at the level of the actin cytoskeleton (data not shown). These data show that TNF-induced TEER loss and shape change require NF-kB inducible protein expression in HDMEC, but they do not directly link ICAM-1 to this process. Our second strategy to connect ICAM-1 to TNF-mediated responses involved the use of siRNA to specifically reduce ICAM-1 expression. We analyzed four different siRNA sequences specific to ICAM-1 and compared our results to an irrelevant siRNA (nuclear lamin A; siRNA sequences are listed in Table S1 ). Unfortunately, the oligofectamine-based transfection procedure itself caused a significant fall in TEER making it impossible to unambiguously assign effects to specific siRNA molecules with this assay. However, transfection did not alter cell shape. In this case, three different siRNA sequences that reduced ICAM-1 expression (without affecting E-sel; data not shown) did reduce the extent of cell elongation caused by TNF (Table 5) . However, the magnitude of the effects on ICAM-1 expression and cell elongation did not strictly correlate. This was evident with siRNA 731 which could reduce the level of ICAM-1 surface expression without blocking shape change. These data support a role for ICAM-1 in mediating the TNF effects on the HDMEC cytoskeleton, but indicate that other proteins requiring NF-kB activation for their TNF-inducible expression are also involved in this response.
DISCUSSION
We hypothesized that induction of ICAM-1 can cause leakiness in HDMEC monolayers and present data showing that retrovirally transduced ICAM-1 causes reduced TEER and overt alterations to the actin cytoskeleton and endothelial junctions. Compared to ICAM basal control and E-sel, leak was increased at TNF-inducible levels of ICAM-1 expression (ICAM med ), measured as a significant (425%) fall in TEER and a doubling of the transmonolayer flux rate of FITC-BSA (Figure 1 ). At high levels of ICAM-1 expression, thickening of the actin stress fibers was visibly apparent (Figure 2) . Moreover, this change was correlated with a transition from the detergent soluble to the detergent insoluble fraction that we measured as an increased F/G actin ratio. High levels of ICAM-1 expression also produced quantifiable gaps in ZO-1 and VE-cadherin immunostaining (Figure 3 and Tables 3 and  4) . Finally, we show that the effects of ICAM-1 overexpression on TEER and the actin cytoskeleton reside, at least in part, outside of the ICAM-1 cytoplasmic tail (Figure 4 ).
The ability of ICAM
DCyto to reduce TEER was unexpected. Such effects are presumably mediated by interactions of the extracellular and/or transmembrane regions of ICAM-1 with other membrane proteins. Possible interactive targets include junctional proteins and/or other transmembrane proteins (including full-length endogenous ICAM-1) that couple to the cytoskeleton. The effect of ICAM DCyto on actin reorganization was variable (data not shown). Although we did not directly compare ICAM DCyto expression among different transductants, our data would suggest that such differences (like those of ICAM med on endothelial junctions) may derive from differences in the level of ICAM-1 expressed. We have been unable to assess the effect of overexpressing the ICAM-1 cytoplasmic domain directly. A chimeric construct consisting of the ICAM-1 cytoplasmic domain linked to the extracellular and transmembrane domains of E-sel, showed TEER equivalent to that of ICAM basal , but because expression levels were consistently and considerably less than that of ICAM med , it was not possible to definitively assess the role of the ICAM-1 cytoplasmic domain. Experiments using dominant-negative peptides based on the ICAM-1 cytoplasmic domain have been inconsistent (unpublished observations, MSK).
An important message of these studies is that leakiness does not appear to require major cytoskeleton-based changes in cell shape or major alterations in junctional protein organization. This conclusion is based upon differences in ICAM-1 (and TNF) levels needed to change these parameters (Table 1 and Figures 2a, 5e and f), and upon different time courses of TNF needed for their occurrence (Figure 5b and c) . And based on examination and analysis of cell-cell junctions, leakiness does not appear to require major alterations to junctional protein organization (Figure 3 ; Tables 2 and 3 ). The observed differences suggest either that barrier function can be regulated independently from the cytoskeleton, or that a greater signal strength, operating through the same mechanism, is necessary for evoking shape change than vascular leak. In other words, our data do not rule out the possibility that the actin cytoskeleton could be a common mediator of both responses, potentially altering junctional proteins in a manner not detectable by the assays used in this study.
Having established that ICAM-1 expression can cause vascular leak, we then investigated whether increased expression of ICAM-1 contributes to the development of vascular leak in response to the proinflammatory cytokine TNF. Our most direct observations in support of this concept are that HDMEC expressing levels of ICAM-1, but not of E-sel, comparable to those induced by TNF show both a loss of TEER and an increase in the passage of BSA proportional to their level of ICAM-1 expression. Transduction of ICAM-1 also produced visible changes in the actin cytoskeleton, measured as an elongation in cell shape, and an increased F/G actin ratio, that were quantitatively similar to those seen in TNF-treated cells. The contribution of ICAM-1 to the effects of TNF on TEER was further supported by the ability of SRIkB, a super repressor of NF-kB activation, to block both TNF induction of ICAM-1 expression and TNF reduction of TEER. However, ICAM-1 is likely to account only partially for the effect of TNF on TEER, because TEER was reduced at lower TNF concentrations than were needed to induce ICAM-1 expression. TNF-induced shape change also was reduced by specific siRNA knockdown of ICAM-1 expression. However, once again, this activity of ICAM-1 is likely to account only partially for the effect of TNF, as an equivalent shape change required higher levels of ICAM-1 in transductants than in TNF-treated HDMEC, and because the effects of siRNA knockdown of ICAM-1 expression were not fully concordant with effects on cell shape. Our approaches taken to reduce ICAM-1 expression or effects have limitations. Our SRIkB HDMEC are fully refractory to TNF-induced permeability, consistent with a contributory role for ICAM-1 in TNFinduced leak, but this approach inhibited TNF-induced synthesis of many proteins in addition to ICAM-1. SiRNA experiments, which are more specific to ICAM-1, may be complicated by unpredictable off-target effects (the siRNA oligomer that knocked down ICAM-1 without affecting shape change may have induced a compensatory off target effect that went undetected). We addressed this by using four different sequences that were screened to rule out strong induction of interferon-related genes. Despite these limitations, the similar outcome from these different approaches strengthens our primary conclusion, namely that increasing ICAM-1 expression induces vascular leak and shape change. Additionally, these data suggest that in the context of EC activation by TNF treatment, increased ICAM-1 expression may contribute to the effects of TNF on vascular leak through cytoskeletal re-organization. It is clear from our studies that changes in TEER and HDMEC shape following TNF require new, NF-kB-dependent protein synthesis. In this regard our data differ from a recent study in which reduction of TEER by TNF required ezrin/ radixin/moesin phosphorylation, detected before induction of ICAM-1 expression by TNF (Koss et al., 2006) . Our data also differ from another study that reported rapid, rho-dependent responses to TNF in HUVEC (Wojciak-Stothard et al., 1999) . Factors that may explain these differences are that we used a different EC type, namely HDMEC, that form an effective barrier to passage of electrical current, and that our transwell measurements were not performed until maximal levels of TEER were reached at 48-96 hours post-confluence. It will be important to investigate whether or not changes in EC permeability owing to ICAM-1 occur independently from changes owing to TNF-induced ezrin/radixin/moesin phosphorylation or Rho activation. Our data suggest that the mechanism and speed of these TNF effects differ from that of thrombin, a trimeric G-protein coupled receptor ligand that acts in minutes and is not affected by blocking NF-kB. We also believe that previously described inhibitory effects of pertussis toxin on TNF-induced leakiness (Brett et al., 1989) may be better explained by the elevation in cAMP produced by pertussis toxin than by any direct effect on TNF signaling.
Previous reports have shown that adenoviral transduction of EC with SR-IkB render EC sensitive to TNF-mediated apoptosis (Ferran et al., 1998; Deshpande et al., 2000) . We did not observe this in our experiments. TNF-treated SRIkB-HDMEC were fully resistant to substrate-detachment as assessed by phase microscopy, to nuclear condensation, and fragmentation by fluorescence microscopy of 4 0 ,6-diamidino-2-phenylindole, dihydrochloride staining, and to loss of membrane integrity by propidium iodide dye exclusion (unpublished observations, PRC and MSK). A possible explanation for their escape from apoptosis is that blockade of NF-kB activation was incomplete, either owing to a lower level of SR-IkB achieved with retroviral transduction than with adenovirus transduction or plasmid transfection, or owing to use of a mouse rather than a human SRIkB construct. Indeed, we did not see total inhibition of ICAM-1 expression ( Figure S2 ), nor did we see a complete loss of cellular FADD-like IL-1b-converting enzyme-inhibitory protein (c-FLIP) expression (unpublished observations, MSK and PRC), a key NF-kB-dependent antiapoptotic protein. It has been reported that post-confluent HUVEC expressing SRIkB can resist apoptosis after TNF treatment (Cota-Gomez et al.,
2002
) and that VEGF can promote EC survival under confluent conditions (Spyridopoulos et al., 1997; Carmeliet et al., 1999; Grazia Lampugnani et al., 2003) . Thus, either VEGF present in the growth medium or our use of postconfluent HDMEC may have counter-balanced the TNF signal for apoptosis as well. Whatever the explanation, our data suggest targeting endothelial NF-kB is a potential antiinflammatory therapy so long as blockade is incomplete.
A final point of discussion is that our in vitro experiments do not take into account the possible contributions of leukocytes to vascular leak. We noted that ICAM-1 knockout mice show less leakiness at sites of inflammation in contact sensitivity responses (Sligh et al., 1993; Xu et al., 1994) . This may well result from the absence of ICAM-1-stimulated leukocyte activation rather than (or in addition to) its role within EC. Indeed, many of the previous studies linking NFkB to vascular leak are better explained as effects on protein (e.g., cytokine) synthesis by leukocytes rather than on EC effects (Moine et al., 2000; Gautam et al., 2001; Lentsch and Ward, 2001) . However, these studies do not rule out a role for activation of NF-kB in EC. For example, exogenous administration of secretory leukocyte protease inhibitor, a naturally occurring NF-kB inhibitor expressed by EC, inhibits vascular leak in vivo and attenuates pulmonary vascular expression of ICAM-1 without affecting macrophage NF-kB (Lentsch et al., 1999; Lentsch and Ward, 2001) . Moreover, leak can occur without leukocytes present, for example in settings of neutropenia (Ognibene et al., 1986) . More pertinent to this study, leukocyte ligand engagement may induce ICAM-1 oligomerization, contributing to ICAM-1-mediated signaling by clustering endothelial ICAM-1 molecules (Wojciak-Stothard et al., 1999; Barreiro et al., 2002) . However, it is possible that at sufficiently high levels of expression, ICAM-1 may spontaneously oligomerize on EC and signal without leukocyte engagement (Yang et al., 2004) and like TNF receptors that are normally activated by ligandinduced clustering (Gaeta et al., 2000) , may spontaneously signal when simply overexpressed in EC. Leukocyte-independent clustering may potentially explain why the responses we observed with ICAM-1 transduction in vitro without leukocytes present required higher concentrations of ICAM-1 than are necessary in vivo, and if clustering does underlie the fall in TEER at high levels of ICAM-1 expression, then it would be expected to occur in ICAM DCyto , which retains both of the extracellular domains believed to promote dimerization (Yang et al., 2004) .
In conclusion, we have presented evidence that increased ICAM-1 expression on HDMEC can mediate vascular leak and cell shape change, a putative means of coordinating leakiness with leukocyte recruitment. However, our data also suggest that while increased ICAM-1 expression may underlie some of the EC effects of TNF, it is unlikely to be the only TNF-induced protein that contributes to such changes.
MATERIALS AND METHODS
Reagents
TNF was obtained from R&D Systems (TNFa, Minneapolis, MN) and recombinant bovine thrombin from Amersham Biosciences Corp (Piscataway, NJ). Unless specified, all other reagents were from Sigma-Aldrich Corp. (St Louis, MO) .
HDMEC cultures
All human materials were obtained with patient consent and in compliance with the Declaration of Helsinki Principles under protocols approved by the Yale Human Investigations Committee. HDMEC were liberated from the superficial vascular plexus of the upper dermal layers of normal adult human skin obtained from discarded surgical specimens by dermatome, followed by digestion with Dispase (50 U/ml; BD Biosciences, San Jose, CA) for 30 minutes at 371C and fine mincing as described previously (Kluger et al., 1997) . Released cells were cultured on 10 mg/ml human plasma fibronectin-coated plastic (Falcon, Lincoln Park, NJ) in EGM2-MV growth medium (Cambrex; East Rutherford, NJ). After 5-7 days in primary culture substrate-adherent cells were resuspended using trypsin and immunoselected on a mini-magneticactivated cell sorter column using anti-CD-31-biotin followed by streptavidin-magnetic beads (Miltenyi Biotec, Auburn, CA). Immunoselected HDMEC were serially passaged on 0.1% gelatin-coated plastic and 499% free of contaminating leukocytes as assessed by immunohistochemistry and FACS analysis. In response to TNF, HDMEC uniformly upregulate ICAM-1 and VCAM-1 and express E-sel. The majority of the cells concomitantly express both venular (E-sel/CD62E, CD34) and lymphatic (podoplanin, Prox-1) markers. Confluent HDMEC monolayers develop well-formed inter-EC contacts that stain with mouse anti-human PECAM-1 (CD31) antibody (DAKO, Carpinteria, CA) adherens junctions that stain with goat anti-human VE-cadherin (CD144) antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and tight junctions that stain with mouse anti-human ZO-1 (Zymed Laboratories, Inc., San Francisco, CA), features of blood vascular EC. As a result, HDMEC monolayers attain higher levels of TEER than HUVEC, which unlike cultured blood microvascular EC, lack tight junctions (Blum et al., 1997) . HDMEC were used between passage four through eight for the experiments described.
Retroviral transduction of HDMEC
Inserts for the translated region of human adhesion molecules ICAM-1 (gift of D. Altieri, University of Massachusetts Medical School, Worcester, MA) and human E-sel (Kluger et al., 2002) (Kluger et al., 2002) or (for the pBMN constructs only) with 1 mg/ml G418 selection (Invitrogen, Carlsbad, CA). phenylindole, dihydrochloride (Molecular Probes, Carlsbad, CA) for 1 hour at room temperature. The same procedure, but with phalloidin-594 (also Molecular Probes) diluted 1:60 in buffer was followed for visualization of the actin cytoskeleton in HDMEC grown on human plasma fibronectin-coated glass cover slips. Fluorescence images, digitally captured with a Zeiss Axiovert 200M microscope networked to a Macintosh G4 computer using OpenLab software, version 4.0.3, were morphometrically analyzed by ImageJ 1.32 software (http://rsb.info.nih.gov/ij/). Cell shape, specifically the degree of elongation relative to a perfect circle, was measured in a blinded manner as an axis ratio (also termed ''aspect ratio''), defined as the ratio of the maximally long cell axis to a bisecting, perpendicular axis, as performed by others (Yu et al., 1997; Wojciak-Stothard and Ridley, 2003) . The patterns of ZO-1 and VE-cadherin distribution on HDMEC monolayers fixed in 95% ethanol/5% acetic acid and immunostained as described above were measured on 6-16 high power ( Â 63 objective) fields per transductant using ImageJ 1.32 (Macconi et al., 2006) .
FACS analysis
Quantification of F-and G-actin by immunoblot analysis
Confluent monolayers of wild-type (treated7TNF for 24 hours) or transduced HDMEC lines were washed at room temperature with 1 Â PBS containing 1 mg/ml phalloidin (Sigma) to prevent filament disassembly, and soluble G-actin was extracted from the cells with actin extraction buffer I (1 Â PBS/1% Triton X-100/2 mg/ml phalloidin) for 2 minutes as described (Cramer et al., 2002) . Lysates were collected and the monolayers were washed three more times. Insoluble F-actin was extracted with Actin Extraction Buffer II (1 Â PBS/1% Triton X-100/2% SDS). Extracted protein lysates were resolved by SDS-PAGE and proteins were transferred to Immobilon-P polyvinylidene fluoride (Millipore, Bedford, MA). After blocking in 5% non-fat milk (Bio-Rad, Hercules, CA), b-actin was detected on the membrane using mouse anti-human b-actin mAb (Sigma: Clone AC-74). Band intensity was quantified using a Molecular Dynamics Densitometer and MD ImageQuant v3.31 software.
SiRNA knockdown
HDMEC were plated on to gelatin-coated 12-well plates at approximately 50% confluence. Mixtures of Oligofectamine to 20 ml/ml and siRNA to 50 nM were prepared in Opti-MEM I Reduced Serum Medium (all from Invitrogen). At 24 hours post-plating, concentrated mixtures of siRNA complexes (Dharmacon Inc., Chicago, IL) were diluted 5-fold to a siRNA concentration of 10 nM before co-incubation with HDMEC cultures for 6 hours at 371C. Fresh medium was added overnight and cells were re-transfected 24 hours later, rested for 24 hours, and then treated with 10 ng/ml human TNF for 24 hours before morphometric analysis or immunostaining followed by FACS analysis. The four siRNA used to specifically target ICAM-1 (Vickers et al., 2003) did not inhibit TNFinduced expression of E-sel (data not shown).
Statistical analysis
Significance of differences among two groups was tested by an unpaired t-test and among more than two groups, by one-way analysis of variance (ANOVA) followed by the Dunnet's post-test in single variable experiments, or by two-way ANOVA followed by the Bonferroni post-test in two variable experiments. P-values o0.05 were accepted as significant. All results were computed using Prism version 4.0c and are presented as means7SEM. A sigmoid curve nonlinear fit analysis was used to describe the concentration dependence of TNF-induced changes in ICAM-1 expression, leakiness, and shape measured on replicate cultures.
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SUPPLEMENTARY MATERIAL Figure S1 . FACS analysis of ICAM DCyto expression on HDMEC. Figure S2 . ICAM-1 surface expression on SRIkB-and enhanced green fluorescent protein-transduced HDMEC after TNF (10 ng/ml for 24 hours). Table S1 . SiRNA reagents used.
